If you've survived a heart attack, there's a good chance you're doing almost everything a cardiologist could ask of you. You're taking your statin. Maybe a blood thinner, a beta blocker. You've probably changed how you eat, how much you move, maybe even quit smoking. And somewhere in the back of your mind, a question keeps surfacing: is this actually enough to stop it from happening again?
That question isn't irrational. It's backed by real numbers. In the United States, roughly 335,000 heart attacks each year are recurrences, not first events. About 1 in 5 people who survive a heart attack will be hospitalized for a second one within five years. And here's the part that catches a lot of people off guard: a meaningful share of that risk remains even in patients who are doing everything textbook-correctly, including keeping their LDL cholesterol at goal.
This article is about that gap, what doctors call "residual risk", and about one specific, measurable reason it exists for millions of people: a blood particle called lipoprotein(a), or Lp(a), that almost never gets tested and that today's standard treatments barely touch.
Have High Lp(a) and a History of Heart Disease?
A Phase 3 clinical trial is currently enrolling adults with elevated Lp(a).
What secondary prevention actually does well
To be clear from the outset: standard post-heart-attack care works, and it works well. Statins lower LDL cholesterol, which drives a large share of atherosclerosis, the plaque buildup that causes heart attacks in the first place. Add antiplatelet therapy, blood pressure control, and lifestyle changes, and the drop in recurrent events compared to a few decades ago is substantial. None of what follows in this article is an argument against that treatment. It's about what happens after you've done all of it and the risk still isn't zero.
The part your treatment plan probably isn't addressing
Researchers use the term "residual risk" for exactly this scenario, the cardiovascular risk that remains after LDL cholesterol and other standard risk factors are well controlled. One widely cited analysis of statin-treated patients with established cardiovascular disease found a modeled five-year risk of a repeat event of about 21%, and in the real-world follow-up group behind that model, 16% actually had one within roughly four years. That's a substantial fraction of people doing the right things and still facing real risk.
When researchers looked at what predicted who would fall into that residual-risk group, one factor came up again and again alongside things like diabetes control and family history: Lp(a).
The Genetic Risk Factor That Doesn't Show Up on a Standard Test
Lp(a) is a cholesterol-carrying particle, structurally similar to LDL, but with an extra protein attached that changes everything about how it behaves. Unlike LDL, which is heavily influenced by diet, weight, and exercise, your Lp(a) level is almost entirely set by your genes, specifically, a single gene called LPA. It reaches a stable, lifelong level within your first few months of life and then, for the vast majority of people, never meaningfully changes again, no matter what you eat or how often you exercise.
About one in five people worldwide has an elevated Lp(a) level. That makes it one of the most common inherited risk factors in cardiovascular medicine and one of the least discussed, for a simple reason: a standard lipid panel does not measure it. You can have a completely normal LDL, HDL, and triglyceride result and still have a high Lp(a), because it's a separate line item that requires its own specific blood test, one most people are never offered unless they specifically ask or a doctor is following newer lipid guidelines closely.
It gets more frustrating from there. Statins, the cornerstone of post-heart-attack treatment, do essentially nothing to lower Lp(a). In one study of stroke patients on statin therapy, Lp(a) levels actually increased in just over half of patients during follow-up. The same study found that people with a high Lp(a) level had two to three times the risk of a repeat vascular event compared to those with lower levels, including among patients whose LDL was already well controlled. In other words: the pill that's protecting you from one kind of risk isn't touching this one at all.
Why Your Body Makes Lp(a) in the First Place
Here's where the story gets genuinely interesting, and it helps explain why Lp(a) exists at all.
Lp(a) was discovered in 1963 by a Norwegian physician named Kåre Berg, who noticed a distinct inherited blood marker while studying family traits. What's stranger is where it shows up: Lp(a) is found almost nowhere in the animal kingdom except humans, Old World primates, and, for reasons that still puzzle researchers, the European hedgehog. Every other mammal gets by perfectly well without it.
So why do we have it? The leading theory is that Lp(a) evolved as a wound-healing tool. Its structure lets it bind tightly to fibrin, the protein scaffolding your body builds at the site of an injury, and effectively deliver cholesterol straight to the wound to help rebuild damaged tissue. In a world without modern medicine, a particle that rushes extra repair material to an injury site could plausibly have been a survival advantage.
The problem is that your arteries, when they develop the microscopic injuries that kick off atherosclerosis, look a lot like a wound to this particle. Lp(a) responds the way it always has: it sticks around and deposits cholesterol at the site. Except now there's no wound to heal, just an artery wall slowly accumulating plaque. A mechanism that may once have helped us survive is, in this context, actively working against us. It's a genuinely elegant piece of biology gone wrong, not so much a design flaw as a tool being used in a context evolution never accounted for.
Why This Matters Most If You've Already Had a Heart Attack
If you've had a heart attack, stroke, or another cardiovascular event, current guidelines already say you're the kind of patient who should know your Lp(a) level. This isn't a "test it someday if you're curious" situation. It's a specific piece of information about your ongoing risk, right now. Research has most clearly shown Lp(a)'s role in this exact group, because your risk of another event is already higher than average, and a high Lp(a) adds to that risk rather than starting from scratch.
That's very different from a healthy person with no heart history wondering whether to get tested out of curiosity. If you've already had an event, a high Lp(a) is one of the clearest, best-supported answers available today to the question "why did this happen to me again?" And it's one of the few pieces of that answer your doctor can actually go looking for.
What You Can Do About It Today
Right now, there's no medication approved specifically to lower Lp(a). That's still true even though scientists have understood the biology for years. So what does that leave you with?
Get tested, just once. Since your Lp(a) level is set by your genes, you typically only need to check it one time in your life. Several major guidelines, including European, Canadian, and National Lipid Association recommendations, now suggest everyone get tested at least once. U.S. guidelines are narrower and focus on people with a personal or family history of early heart disease that other risk factors don't fully explain. If you've had a heart attack, that likely includes you.
Take control of everything you can change. This is the hopeful part. A large study of the general population (EPIC-Norfolk) found that people with high Lp(a) who kept up an otherwise healthy lifestyle, a healthy weight, good diet, regular activity, not smoking, and controlled blood pressure and blood sugar, had only about a third of the cardiovascular risk compared to people with poor overall heart health, no matter their Lp(a) level. You can't lower the number itself yet, but you can change a lot about what it means for you.
Tell your close family. Since Lp(a) is directly inherited, your parents, siblings, and children have a real chance of having the same level you do. One conversation and one blood test could change how they think about their own risk, especially if early heart attacks run in your family without a clear reason why.
What's New in Lp(a) Research Right Now
The gap between understanding this risk factor and being able to treat it is exactly what current research is trying to close. Several drugs designed specifically to lower Lp(a) are now in late-stage (Phase 3) clinical trials, using a few different approaches: some are injectable therapies that reduce how much Lp(a) the liver makes, while others work orally.
One example currently enrolling in the U.S. is a Phase 3 study of muvalaplin, sponsored by Eli Lilly, in adults with high Lp(a) who either have a history of a prior cardiovascular event or are otherwise at high risk for a first one. The study page shows the full design, eligibility criteria, and current recruiting locations. It's one of several active studies in this space, and browsing what's currently enrolling for cardiovascular disease or specifically coronary artery disease is a reasonable next step, whether or not this particular trial ends up being the right fit for you.
The Bottom Line
Doing everything your cardiologist has asked and still worrying about a second heart attack doesn't mean you're doing something wrong. It may just mean there's a piece of your risk profile that standard care was never built to address. Lp(a) is common, it's easy to test for, and it runs in families. For the first time in the six decades since it was discovered, it's finally being targeted by treatments in active development. Knowing your number is the part you can act on today. What comes after that is what researchers are racing to figure out.
Frequently Asked Questions
What is Lp(a)? Lp(a), or lipoprotein(a), is a cholesterol-carrying particle in your blood, similar to LDL but with an added protein that makes it independently linked to heart attack and stroke risk. Its level is set almost entirely by genetics.
Is Lp(a) part of a standard cholesterol test? No. A routine lipid panel measures LDL, HDL, and triglycerides, but not Lp(a). It requires its own specific blood test, which you can ask your doctor to order.
Can I lower my Lp(a) with diet or exercise? Not meaningfully. Because Lp(a) is genetically determined, lifestyle changes have very little effect on the level itself, unlike LDL cholesterol. Lifestyle changes still matter, though, for managing your overall cardiovascular risk around that fixed Lp(a) level.
Do statins lower Lp(a)? No. Statins are highly effective at lowering LDL cholesterol but have little to no effect on Lp(a), and in some patients, Lp(a) can even rise slightly while on statin therapy.
How often do I need to get tested? Generally just once in your lifetime, since Lp(a) levels are set early on and remain fairly stable afterward.
Is there a treatment for high Lp(a) yet? Not one approved specifically for lowering Lp(a) itself. Current management focuses on aggressively controlling every other modifiable risk factor. Several Lp(a)-lowering drugs are in late-stage clinical trials.
Should my family get tested too? It's worth discussing, especially if you have a confirmed high Lp(a) or a family history of early heart attacks or strokes. First-degree relatives (parents, siblings, children) have a meaningful chance of sharing an elevated level.